Get the Stockscreener App
0.3602
8.83%
-0.0349
After Hours:
.36
-0.0002
-0.06%
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Layoff Tracker: CRISPR, Cytiva Laying Off Employees - BioSpace
How pharma CEO pay shifted for these 4 companies last year - PharmaVoice
Atria Wealth Solutions Inc. Buys New Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
President and CEO Polymeropoulos Mihael Hristos bought $47,600 worth of shares (10,000 units at $4.76), increasing direct ownership by 0.43% to 2,361,730 units (SEC Form 4) - Quantisnow
ANI Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) - Yahoo Finance
The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease - Quantisnow
Earnings call transcript: Xenon Pharmaceuticals Q4 2024 sees slight EPS beat - Investing.com
Financial Survey: X4 Pharmaceuticals (NASDAQ:XFOR) & Tourmaline Bio (NASDAQ:TRML) - Defense World
President and CEO Polymeropoulos Mihael Hristos bought $47,650 worth of shares (10,000 units at $4.76), increasing direct ownership by 0.43% to 2,341,730 units (SEC Form 4) - Quantisnow
Popular lemonade recalled by FDA for cancer-linked chemical - New York Post
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update - Business Wire
President and CEO Polymeropoulos Mihael Hristos bought $44,640 worth of shares (10,000 units at $4.46), increasing direct ownership by 0.43% to 2,331,730 units (SEC Form 4) - Quantisnow
Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences - Business Wire
SVP, CFO & Treasurer Moran Kevin Patrick bought $8,779 worth of shares (2,000 units at $4.39), increasing direct ownership by 0.57% to 355,763 units (SEC Form 4) - Quantisnow
3 Pharmaceutical Stocks With Blockbuster Drug Potential - TradingView
Licensing For Innovation: A Decade Of Pharma Product Deals - Insights
Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 - Business Wire
DeFloria Receives Investigational New Drug Application Clearance from FDA for Phase 2 Clinical Trial of AJA001, an Oral Cannabinoid Drug Being Developed for the Treatment of Autism Spectrum Disorder (ASD) - PR Newswire
Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" - Morningstar
SVP, CFO & Treasurer Moran Kevin Patrick was granted 125,000 shares, increasing direct ownership by 55% to 353,763 units (SEC Form 4) - Quantisnow
X4 Pharmaceuticals, Taiba to Distribute Xolremdi in Select Middle East Countries -February 19, 2025 at 10:56 am EST - Marketscreener.com
X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries - Marketscreener.com
X4 Pharmaceuticals and Taiba Rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI®? in WHIM Syndrome in Select Middle East Countries - Marketscreener.com
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 22.6% in January - MarketBeat
Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Yahoo Finance
X4 pharmaceuticals chief commercial officer Mark Baldry acquires $19,251 in stock By Investing.com - Investing.com South Africa
X4 pharmaceuticals chief commercial officer Mark Baldry acquires $19,251 in stock - Investing.com India
HC Wainwright Cuts Earnings Estimates for X4 Pharmaceuticals - MarketBeat
Fierce Biotech Layoff Tracker 2025: Encoded trims 29% of team; Inventiva halves staff - Fierce Biotech
SG Americas Securities LLC Increases Stock Holdings in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) - Defense World
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025 - Business Wire
Finance Watch: Third Harmonic, Q32 Bio Cut Jobs To Focus On Lead Assets - News & Insights
FY2027 EPS Forecast for X4 Pharmaceuticals Cut by Analyst - Defense World
FY2028 Earnings Estimate for XFOR Issued By HC Wainwright - Defense World
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion - Business Wire
X4 Pharmaceuticals Inc (XFOR) Performance and Fundamentals Dashboard tells a completely different story - SETE News
Is X4 Pharmaceuticals Inc (NASDAQ:XFOR) stock a better investment at this time? - US Post News
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
X4 Pharmaceuticals Inc [XFOR] Records 200-Day SMA of $0.7110 - Knox Daily
X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia - Marketscreener.com
X4 Pharmaceuticals Stumbles Again, Laying Off 30% of Workforce - BioSpace
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for LYMPHIR by Centers for Medicare and Medicaid Services - PR Newswire
X4 lays off 30% of staff to focus on Xolremdi rollout - Fierce Biotech
6.45%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):